Search results for: 'security screening systems xaas global'

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

24 Oct 2018  |  North America  |  Market Research

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

Infographics

×

Key Issues Addressed

The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...

This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.

11 Jun 2015  |  North America  |  Market Research

Analysis of the Western European Laboratory Information Management System Market

Cloud-based Technology and Increasing Need for Large Genetic and Molecular Testing Data Management to Drive the Market

Infographics

×

The research analyses the laboratory information management system (LIMS) market in Western Europe. It discusses the evolving market trends - the need for integration and the ever increasing sample data across labs in Western Europe. The study provides market overview, market engineering measurements, revenue forecasts, and company profiling. The s...

Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are work...

29 Mar 2016  |  Global  |  Market Research

Top 50 Emerging Technologies: Growth Opportunities of Strategic Imperative

Multi-billion dollar technologies ready to propel industries and transform our world

Infographics

×

Research Overview The Top 50 Emerging Technologies research is a comprehensive analysis of the most promising and disruptive technologies poised to impact our world in the next few years. It highlights and offers strategic guidance and actionable ideas on the hottest 50 technologies that pack maximum potential to fuel global innovation; spawn in...

03 Feb 2021  |  North America  |  Market Research

Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-generation Sequencing (NGS) Market

Next-generation Blockchain-Powered Genomic Data Marketplaces are Creating New Growth Opportunities

Infographics

×

2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains unconq...